ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $836,392 | +6.5% | 8,932 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $785,400 | +46.5% | 8,800 | +76.0% | 0.00% | 0.0% |
| Q1 2023 | $536,100 | +58.0% | 5,000 | +79.9% | 0.00% | – |
| Q4 2022 | $339,399 | -51.0% | 2,779 | -52.9% | 0.00% | -100.0% |
| Q1 2022 | $692,000 | +207.6% | 5,900 | +318.4% | 0.00% | – |
| Q3 2021 | $225,000 | -60.4% | 1,410 | -67.3% | 0.00% | – |
| Q2 2021 | $568,000 | +2.2% | 4,314 | +0.0% | 0.00% | – |
| Q1 2021 | $556,000 | -22.7% | 4,313 | +0.1% | 0.00% | – |
| Q4 2020 | $719,000 | +5.7% | 4,310 | -2.0% | 0.00% | – |
| Q3 2020 | $680,000 | -42.5% | 4,399 | -44.9% | 0.00% | -100.0% |
| Q2 2020 | $1,182,000 | +52.7% | 7,990 | +16.3% | 0.00% | 0.0% |
| Q1 2020 | $774,000 | -64.1% | 6,869 | -55.7% | 0.00% | -50.0% |
| Q4 2019 | $2,156,000 | +436.3% | 15,504 | +271.2% | 0.00% | – |
| Q3 2019 | $402,000 | +33.1% | 4,177 | -72.2% | 0.00% | – |
| Q3 2016 | $302,000 | +42.5% | 15,031 | -6.2% | 0.00% | – |
| Q2 2016 | $212,000 | +14.0% | 16,030 | +60.0% | 0.00% | – |
| Q1 2016 | $186,000 | -9.3% | 10,016 | -10.7% | 0.00% | – |
| Q4 2015 | $205,000 | – | 11,220 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |